Dementia Consortium

The Dementia Consortium will provide funding, resources and expertise to both increase the number of, and capitalise upon, new drug targets emerging from across the academic sector that hold promise of bringing patient benefit.

The Dementia Consortium members are Alzheimer’s Research UK, technology transfer and drug discovery experts Evotec and the pharmaceutical companies, Abbvie, Astex, Eisai, Johnson & Johnson, Lilly and MSD.

For target validation and drug discovery projects, please apply via the Dementia Consortium.

The duration and amount will be determined at full application stage. We anticipate typical projects to be up to two years in duration and cost £100,000-£250,000. There is a notional limit of £500,000 for exceptional cases.

Apply now

Application FAQs

Applications are acceptable from applicants based at established research institutions worldwide. The Lead Applicant is expected to have a contract (fixed term or tenure) which covers the proposed duration of the grant. If the Lead Applicant does not hold a tenure appointment, the application must include a co-applicant that does.

There are regular deadlines for Expressions of Interest. Please see for more information and to request an Expression of Interest form.

Applications are made via our grant application website.

The progression of each application is assessed by the Dementia Consortium partners and all full applications are subjected to external peer review. Applications are sent to researchers in the UK and worldwide who specialise in the area of the application, but who do not have a conflict of interest.

The terms and conditions of grant differ for each grant scheme and contracts are drawn up individually once the grants have been awarded.


Dementia Consortium projects are monitored regularly by Evotec and Alzheimer’s Research UK.

For more information about any of the grant schemes or the application process please contact the Research Team or 0300 111 5555

Up to £250,000

Provides researchers with the funding, resources and expertise to capitalise on emerging drug targets.

Key Dates